Aspen flags FY2026 normalized EBITDA up 7%-12% to R 7.46 billion-R 7.81 billion

• Aspen flagged FY 2026 normalised EBITDA from continuing operations up 7%-12% to R 7.46-7.81 billion.
• NHEPS from continuing operations seen up 19%-24% to 784.4-817.4 cents; first-half NHEPS had fallen 25%.
• Total-operations NHEPS forecast up 7%-12% to 1,129.8-1,182.6 cents; HEPS expected down 24%-19% to 602-641.6 cents.
• EPS expected above 100% to 550-620 cents from -243.9 cents, lifted by R 2.4 billion profit on the APAC divestment.
• FY 2026 ended with net cash of about R 0.8 billion following R 0.5 billion buybacks; restructuring costs were R 2.3 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspen Pharmacare Holdings Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S601836), on August 21, 2026, and is solely responsible for the information contained therein.